Treating Chronic Hepatitis C in the Primary Care Setting

Abstract

The National Institutes of Health and other institutions have emphasized the need to expand access to treatment of chronic hepatitis C virus infection to a larger and more diverse patient population. To begin to address this need, the divisions of General Internal Medicine and Liver Diseases of the Mount Sinai Medical Center created a program to identify patients who might benefit from hepatitis C treatment, to treat uncomplicated patients in the primary care setting, and to refer appropriate patients to liver disease specialists. Preliminary data from this program suggest that primary care-based treatment of chronic hepatitis C may offer unique advantages. The primary care setting allows special needs to be addressed and allows comprehensive services to be provided. Patients are guided through the complex pretreatment evaluation process, and non-liver-related comorbidities are managed. Our program may provide a useful model for increasing hepatitis C literacy among primary care providers and for extending treatment to a broader population of patients with hepatitis C.

KEYWORDS

Access - comorbidity - hepatitis C - risk factor - treatment - primary care

REFERENCES

• 1 Liang T J, Rehermann B, Seeff L B, Hoofnagle J H. Pathogenesis, natural history, treatment, and prevention of hepatitis C.  Ann Intern Med. 2000;  132 296-305
• 2 UNAIDS .Global Summary of the AIDS Epidemic. New York; United Nations Publication 2004
• 3 Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease.  Semin Liver Dis. 2005;  25 7-17
• 4 Di Bisceglie A. Hepatitis C.  Lancet. 1998;  31 351-355
• 5 National Institutes of Health Consensus Development Conference Statement .Management of Hepatitis C: 2002. Bethesda, MD; The National Institutes of Health August 27, 2002
• 6 Drusano G, Preston S. A 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.  J Infect Dis. 2004;  189 964-970
• 7 Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?.  Ann Intern Med. 2004;  140 370-381
• 8 Jeffers L, Cassidy W, Howell C et al.. Peginterferon alfa 2a (40kd) and ribavirin for black American patients with chronic HCV genotype 1.  Hepatology. 2004;  39 1702-1708
• 9 Sturm T, Federman A, Wisnivesky J et al.. Hepatitis C prevalence and risk factors in an urban primary care practice.  J Gen Intern Med. 2004;  19(supp1) 157
• 10 Garfien R, Vahov D, Galai N et al.. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, HIV, and human T lymphotropic viruses.  Am J Public Health. 1996;  86 655-661
• 11 Dore J, Thomas D L. Management and treatment of injection drug users with hepatitis C virus (HCV) monoinfection and HCV/human immunodeficiency virus coinfection.  Semin Liver Dis. 2005;  25 8-32
• 12 Larson A, Carithers R. Hepatitis C in clinical practice.  J Intern Med. 2001;  249 111-120
• 13 Shehab T, Orrego M, Chunduri R, Lok A. Identification and management of hepatitis C patients in primary care clinics.  Am J Gastroenterol. 2003;  98 639-644
• 14 Shehab T, Sonnad S, Lok A. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey.  J Viral Hepat. 2001;  8 377-383
• 15 U.S. Preventive Services Task Force . Screening for hepatitis C virus infection in adults: recommendation statement.  Ann Intern Med. 2004;  140 462-464
• 16 Falck-Ytter Y, Kale H, Mullen K D et al.. Surprisingly small effect of antiviral treatment in patients with hepatitis C.  Ann Intern Med. 2002;  136 288-292